Clinical trial
CMV Retinitis Retreatment Trial
NCT00000766 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00000766 |
|---|---|
| Title | CMV Retinitis Retreatment Trial |
| Official title | CMV Retinitis Retreatment Trial |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cytomegalovirus Retinitis, HIV Infections |
| Intervention type | Drug |
| Interventions | Foscarnet sodium, Ganciclovir |
| Enrollment | 300 |
| Primary completion | Sep 1, 1995 |
| First posted | Aug 31, 2001 |
| Last update posted | Mar 1, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: